Summary of the Conference Call for New Bridge Bio Company Overview - New Bridge Bio is a biotechnology platform company focused on accelerating the global market value of innovative drugs from China. The company has a pipeline of innovative products covering both first-in-class and best-in-class categories [3][4]. Core Assets - **VIS101**: A bispecific biologic targeting VEGF-A and Ang-2, showing best-in-class potential in clinical trials. It has a dosing interval of 8-24 weeks, significantly better than competitors [2][3]. - **Giva**: A bispecific antibody targeting Claudin 18.2, demonstrating durable anti-tumor responses in clinical trials [3]. Financial Status - The company holds $228 million in cash, sufficient to support operations until the end of 2028, covering multiple key clinical milestones for VIS101 and Giva [2][3]. Clinical Development Plans - **Phase IIb Study**: Planned to start in the second half of 2026, focusing on dose expansion (6mg vs 9mg) [2][13]. - **Global Phase III Study**: Expected to begin in 2027, with discussions ongoing with the FDA regarding the possibility of a single registration trial [2][14]. Clinical Trial Results - **Phase IIa Results for VIS101**: - 64% of patients required no rescue treatment at 4 months, and 49% at 6 months. - Average vision improvement exceeded 10 letters on the ETDRS scale [2][9]. - The study included 38 patients, with significant improvements in both treatment-naive and previously treated patients [11][15]. Competitive Advantages - VIS101's dosing regimen allows for longer intervals between treatments, which is advantageous for patient compliance and healthcare costs [6][12]. - The drug's molecular design offers superior binding affinity, with VEGF-A inhibition 2 times stronger and Ang-2 inhibition 17 times stronger than the competitor's drug [7][8]. Market Potential - The global market for ophthalmic indications targeted by VIS101 is substantial, with millions of patients suffering from conditions like wet AMD and diabetic macular edema [6]. - The anti-VEGF market is well-established, with significant sales figures for existing treatments, indicating a strong potential for VIS101 [6]. Safety Profile - The safety data from clinical trials show a favorable profile, with only two related events reported, none classified as serious adverse events [13]. Commercialization Strategy - New Bridge Bio's unique "Hub-and-spoke" model connects Chinese innovation with global market needs, allowing for flexible commercialization strategies, including licensing and co-development [4][5]. - The company is confident in the commercial prospects of VIS101, given its best-in-class potential and the large market size [21]. Future Data Disclosure - Plans to disclose comprehensive clinical data, including long-term follow-up data (12 months or more), are in place to meet regulatory requirements [22]. This summary encapsulates the key points from the conference call regarding New Bridge Bio's strategic positioning, clinical developments, and market opportunities.